( 18 F-DOPA) is abundantly used for visualizing neuroendocrine tumors and neurologic imaging. This amino acid tracer visualizes those cells that possess the capability to take up the aromatic amino acid precursor and are involved in the biosynthesis of dopamine. 18 F-DOPA has been shown to be a good tracer for welldifferentiated neuroendocrine tumors originating from the gastrointestinal tract (1) (2) (3) . In addition, 18 F-DOPA has also been shown to be a good tracer for other types of neuroendocrine tumors, such as neuroblastoma (4) , medullary thyroid carcinoma, pheochromocytoma, and paraganglioma (1) , and for malignancies of the central nervous system (5) . Finally, imaging dopamine metabolism in the central nervous system with 18 F-DOPA is an effective means to determine the extent of degeneration of presynaptic dopaminergic neurons in Parkinson disease (6) . Despite the general applicability of 18 F-DOPA imaging in nuclear medicine, 18 F-DOPA is available in only a few countries worldwide. The major drawback limiting a more widespread use is its labeling method.
The conventional synthesis of 18 F-DOPA involves an electrophilic substitution of a trialkylstannane precursor with 18 F gas (7, 8) . The difficulty of generating and handling 18 F 2 and the large amount of carrier 19 F-DOPA that is generated during the electrophilic process are major disadvantages, which have led to the development of various nucleophilic substitution protocols for the production of 18 F-DOPA using no-carrier-added fluoride (9) (10) (11) (12) (13) . DiMagno has recently developed a fully elaborated diaryliodonium salt precursor, which allows for the facile production of no-carrier-added 18 F-DOPA via radiofluorination, followed by deprotection (14) .
We applied this method to synthesize 18 F-DOPA ( Fig. 1 ) and tested whether the high-specific-activity product possesses discernibly different biologic behavior and imaging properties in comparison to conventional 18 F-DOPA. This article presents the first comparison of 18 F-DOPA with high specific activity, produced from a diaryliodonium salt precursor ( 18 F-DOPA-H), with conventional, low-specific-activity 18 F-DOPA ( 18 F-DOPA-L) in a biologic model for neuroendocrine tumors.
MATERIALS AND METHODS

Chemicals
All chemicals were obtained from Sigma-Aldrich, unless stated otherwise. Matrigel was obtained from BD Biosciences. The culture medium DMEM (Dulbecco modified Eagle medium) and Ham F-12 were obtained from Invitrogen, Life Technologies. The fetal calf serum was obtained from Bodinco. The phosphate-buffered saline (PBS) used in the experiments was obtained from the Department of Hospital Pharmacy, University Medical Center Groningen. The PBS contained 140 mM NaCl, 9 mM Na 2 HPO 4 , and 1.3 mM NaH 2 PO 4 , and pH was 7.4. For incubation during in vitro experiments GMC (5.6 mM D-glucose, 0.49 mM MgCl 2 , 0.68 mM CaCl 2 ) was added to the PBS. The diaryliodonium precursors for the synthesis of 18 F-DOPA and 6-18 F-fluorodopamine were provided by Ground Fluor Pharmaceuticals. The synthesis and characterization of the diaryliodonium precursor to 18 F-DOPA, ((S)-methyl-3-(4,5-bis(ethoxymethoxy)2-iodophenyl)-2-(di-(tert-butoxycarbonyl))amino)propanoate)(4-methoxyphenyl)-l 3 -iodane trifluoromethanesulfonate (ALPDOPA), are provided in the supplemental materials (available at http://jnm.snmjournals.org).
Radiosynthesis
Experiments were performed with either 18 F-DOPA-L, obtained from the conventional synthesis procedure (electrophilic substitution) as described by de Vries et al. (8) , resulting in a product with a specific activity of 11 6 2 GBq/mmol and a decay-corrected radiochemical yield of 33% 6 4% at the end of bombardment (EOB), or with 18 F-DOPA-H, synthesized via the novel method starting from diaryliodonium salt precursor, resulting in a product with a specific activity of 35,050 6 4,000 GBq/mmol and a decay-corrected radiochemical yield of 14% 6 4% EOB. The radiosynthesis of 18 F-DOPA-H was based on the instructions of the supplier of the precursor, as detailed in the supplemental information. 18 F-DOPA-H was produced in 117 6 4 min at the EOB. Both products were produced with a radiochemical purity higher than 95% and a high enantiomeric purity (enantiomeric excess . 99%).
Cell Culture
In vitro experiments were performed with the human pancreatic neuroendocrine tumor cell line BON-1. The cells were cultured in 25 cm 2 culture flasks containing 5 mL of culture medium (DMEM:Ham F-12:fetal calf serum, 9/9/2). Cells were grown in a humidified atmosphere containing 5% CO 2 and subcultured twice a week.
Cells were harvested by trypsin treatment, resuspended, and plated at a density of 500,000 cells per well in culture medium on 12-well plates at the day before the cell experiment (1 mL/well). The viability and the number of cells were determined with the trypan blue exclusion technique.
Accumulation Experiments in BON-1 Cells
On the day of the experiment, cells were washed with PBS (2 · 1 mL), and 1 mL of PBS-GMC buffer, optionally spiked with a pharmacologic inhibitor, was added per well. The pharmacologic inhibitors were applied in the following concentrations: 1 mM 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH), 80 mM carbidopa, 100 mM pargyline, or 10 mM tetrabenazine. The cells were placed in an incubator for 1 h at 37°C to allow depletion of residual nutrients from the culture medium.
After the 1-h depletion period, 200 kBq of 18 F-DOPA-L or 18 F-DOPA-H, dissolved in a volume of 50 mL of the tracer formulation, were added to each well. The time of addition of the tracer (0, 15, 30, 45, 50, and 55 min after the 1-h depletion period) corresponded with the incubation times of 60, 45, 30, 15, 10, and 5 min, respectively. Afterward, the cells were placed back in the incubator at 37°C. At 60 min, all wells were washed with ice-chilled PBS (2 · 1 mL). To each well, 0.2 mL of 0.05% (w/v) trypsin in PBS was added, and the cells were incubated at 37°C for 5 min. Then 1 mL of culture medium was added. The contents of the wells were resuspended and transferred to 5-mL counting tubes. The radioactivity was measured with a g counter (1282CS; LKB Wallac Compugamma). Then the viability and the number of cells were determined with the trypan blue exclusion technique. The viability was greater than 90% within 2 h after the experiment. The radioactivity in the samples was expressed as the percentage of the added dose per 100,000 cells.
Animals
Male BALB/cOlaHsdFoxn1 nu/nu athymic nude mice (body weight, 18-24 g) were obtained from a breeding facility (Harlan). The animals were housed in temperature-and humidity-controlled rooms with 12-h day and 12-h night cycles. They were provided with forage and water ad libitum. Animals were housed in individually ventilated cages with HEPA filters in the research facility of the University Medical Center Groningen. All animal experiments were done by licensed investigators in compliance with the Law on Animal Experiments of The Netherlands. The study protocol was approved by the Committee on Animal Ethics of the University of Groningen.
Small-Animal PET Experiments in BON-1 TumorXenografted Mice
The nude mice were injected subcutaneously on the right shoulder with an ice-cold tumor cell suspension, consisting of 1 million BON-1 cells in 100 mL of culture medium and 100 mL of Matrigel. Three weeks after inoculation of the tumor, the animals were scanned (smallanimal PET). The tumor growth and the welfare and body weight of the animal were checked regularly in this period (at least 3 times a week).
The 3 experimental groups each consisted of 4 mice. At least 2 h before the start of the small-animal PET scan, the mice were acclimatized to the laboratory conditions. Animals from 2 of 3 experimental groups were pretreated with an intraperitoneal injection of 20 mg of carbidopa in 100 mL of PBS 60 min before the start of the small-animal PET scan. The mice were anesthetized with isoflurane (5% in medical air for induction and 1.5% in medical air for maintenance of anesthesia) before an injection in the penile vein with 1 MBq of either 18 F-DOPA-L (228.3 6 5.7 pmol/g, 1 experimental group) or FIGURE 1. Two-step synthesis of 18 F-DOPA from precursor ALPDOPA, ((S)-methyl-3-(4,5-bis (ethoxymethoxy)2-iodophenyl)-2-(di-(tert-butoxycarbonyl))amino)propanoate)(4-methoxyphenyl)-λ 3 -iodane trifluoromethanesulfonate. Radiochemical yield, 14% ± 4% EOB; enantiomeric excess . 99%. novel 18 F-DOPA-H (0.49 6 0.09 pmol/g, 2 experimental groups). The mice were scanned during 90 min with a Concorde microPET Focus 220 system equipped with microPET Manager software for data acquisition. The dynamic PET scan was followed by a 10-min transmission scan using a 51 Co source. The animals were sacrificed by application of 5% isoflurane in medical air for 15 min, which was applied from the start of the transmission scan. Quantitative analysis was performed using ordered-subset expectation maximization. The PET acquisition data were fully corrected for random coincidences, attenuation, and scatter. The reconstructed PET images were analyzed using Siemens Inveon Research Workplace software. Organs and tissues, including the tumor xenograft, were dissected and measured with a g counter.
In Vivo Stability
After measurement of the radioactivity with the g camera, tissue samples from the brain and the tumor were cut into small pieces and submerged in 0.5 mL of water and 1 mL of acetonitrile in a plastic test tube. After homogenizing the tissue samples with a rotor-stator mixer, the resulting suspension was spun down at 6,000 rpm, and a sample of the supernatant was spotted on a silica plate. The protein content was precipitated by adding 2 volumes of acetonitrile to 1 volume of plasma. Also, samples of the deproteinated plasma and of urine were spotted on a silica plate. The plate was developed with n-BuOH:CH 3 COOH:H 2 O:EtOH 4/1/1.6/ 0.5 (v/v/v/v). The thin-layer chromatography (TLC) plate was dried and placed on a phosphor storage screen, which was exposed overnight. The intensity of the spots on the phosphor storage screen was measured with the Cyclone (Packard Instuments).
Data Analysis
Data represent mean 6 SEM, from n separate experiments. The statistical significance of differences between means was calculated using the Student t test. Differences were considered to be statistically significant when the P value was less than 0.05.
RESULTS
Accumulation Experiments in BON-1 Cells
At 37°C, the uptake of 18 F-DOPA-H did not differ significantly from the uptake of 18 F-DOPA-L. A differential response was revealed when the accumulation experiment was performed at 0°C. The uptake of 18 F-DOPA-L was significantly reduced at 0°C, compared with 37°C at all time points, whereas the uptake of 18 F-DOPA-H was only slightly reduced by changing the temperature at 10 and 15 min (Fig. 2A) .
The selective inhibitor of the L-type amino acid transporter (LAT) BCH lowered the uptake of both 18 F-DOPA-L and 18 F-DOPA-H in a similar fashion (Fig. 2B) .
Carbidopa, an inhibitor of aromatic L-amino acid decarboxylase (AADC), was applied to determine whether inhibition of metabolic conversion to 6-18 F-fluorodopamine affected tracer uptake. Carbidopa significantly decreased uptake of 18 F-DOPA-L at late time points, compared with control. The uptake of 18 F-DOPA-H was not significantly affected by carbidopa (Fig. 2C) .
Pargyline, at the applied concentration a nonselective inhibitor of monoamine oxidase (MAO), did not significantly alter the uptake of 18 F-DOPA-H or 18 F-DOPA-L (Fig. 2D) .
Tetrabenazine, an inhibitor of vesicular monoamine transporter type 2 (VMAT2), led to differential effects between the 2 variants of 18 F-DOPA. It significantly increased the uptake of 18 F-DOPA-H, whereas the uptake of 18 F-DOPA-L was significantly reduced (Fig. 2E) . and other characteristics of the mice belonging to the 3 experimental groups are listed in Table 1 .
On a representative PET image (Fig. 3A) , it is clearly visible that carbidopa increased the uptake of 18 F-DOPA-H in the BON-1 tumor xenograft. The uptake of 18 F-DOPA-L and 18 F-DOPA-H was also high in the pancreas and bladder.
The time-activity curves ( Fig. 3B) reveal that from 45 min onward, carbidopa significantly enhanced the uptake of 18 F-DOPA-H in the tumor. In animals that received carbidopa pretreatment, there was no significant difference in mean standardized uptake value between those that received 18 F-DOPA-H and those that received 18 F-DOPA-L.
The biodistribution data revealed that there were no statistically significant differences between the uptake of 18 F-DOPA-H and the uptake of 18 F-DOPA-L in relevant organs. In tumor and brain, carbidopa pretreatment led to a significant increase in uptake of 18 F-DOPA-H (Fig. 4A) , which also translated into an increased uptake ratio of tumor versus plasma after carbidopa pretreatment (Fig. 4B) .
In Vivo Stability 6-18 F-fluorodopamine was synthesized in the same manner as 18 F-DOPA (Fig. 1) to check its retention factor on radio-TLC. The R f of 18 F-DOPA was 0.43, and the R f of the metabolite 6-18 F-fluorodopamine was 0.54. Tissue samples from the biodistribution experiment were investigated by radio-TLC. The fraction of the administered 18 F-DOPA found in plasma and homogenates of tumor and brain in the form of the metabolite 6-18 F-fluorodopamine was significantly increased after pretreatment with carbidopa in animals that received 18 F-DOPA-H (Fig. 5) . The fraction of 6-18 F-fluorodopamine did not differ significantly between carbidopa-pretreated animals that received 18 F-DOPA-H and those that received conventional 18 F-DOPA-L.
DISCUSSION
The availability of a novel synthesis method to produce 18 F-DOPA from no-carrier-added 18 F-fluoride and a diaryliodonium salt precursor greatly simplifies access to this tracer, because 18 F 2 does not need to be generated or handled. The product, 18 F-DOPA-H, has a considerably higher specific activity (3 orders of magnitude) than the 18 F-DOPA-L, which is produced from electrophilic fluorination. We investigated whether the increase of the specific activity had implications for the biologic behavior of the tracer due to saturation of 1 or more proteins involved in the molecular uptake mechanism of 18 F-DOPA. The uptake of 18 F-DOPA in accumulation experiments in BON-1 cells under control conditions did not differ significantly between 18 F-DOPA-H and 18 F-DOPA-L at the time points within 60 min after addition of the tracer. The accumulation of 18 F-DOPA-L was significantly reduced by lowering the temperature from 37°C to 0°C because of partial inactivation of 1 or more proteins that are involved in the uptake mechanism, whereas the accumulation of 18 F-DOPA-H was unaffected. The extent of cold-induced inhibition was not large enough to reduce the capacity to sequester the 18 F-DOPA-H. To further elucidate the observed cold-induced inhibition, accumulation experiments were performed in the presence of pharmacologic inhibitors of proteins involved in the molecular uptake mechanism of 18 F-DOPA. Figure 6 provides an overview of the cellular uptake mechanism of 18 F-DOPA. The LAT, which is responsible for entry of a variety of amino acids, is a high-capacity transporter. Furthermore, this transporter is upregulated in a wide range of malignant cells (15) . LAT1 expression is associated with poor prognosis (16) (17) (18) as well as metastases and angiogenesis (19) . Because of its high expression in neuroendocrine malignancies, LAT1 is unlikely to be satiated, which is in accordance with the results of the accumulation experiment of 18 F-DOPA after treatment with the specific inhibitor of LAT: BCH led to a decrease of the same extent in both 18 F-DOPA-H and 18 F-DOPA-L.
The expression of AADC is increased in most tumors of neuroendocrine origin as well (4, 20, 21) . The application of carbidopa (inhibitor of AADC) showed a modest decline in uptake for 18 F-DOPA-L, compared with 18 F-DOPA-H, at early time points (5-30 min). In addition, 18 F-DOPA-L is significantly decreased at later time points (30-60 min) after carbidopa pretreatment. The difference in uptake after treatment with carbidopa between 18 F-DOPA-H and 18 F-DOPA-L is limited to the early time points, and therefore the differential response to lowering the temperature from 37°C to 0°C cannot be fully attributed to cold-induced inhibition of AADC.
The expression of vesicular monoamine transporter (VMAT) is inversely correlated with poor prognosis (22, 23) , possibly implying a potential protective function of the VMAT. However, it more likely reflects the extent of differentiation of the tumor as tumor dedifferentiation is accompanied with a poor disease outcome. The application of tetrabenazine (an inhibitor of VMAT2) led to a differential response between 18 F-DOPA-H and 18 F-DOPA-L. The uptake of 18 F-DOPA-L was significantly decreased at late time points (45-60 min) as one would expect from the reduced activity of VMAT2, resulting in a lower sequestration of tracer in the secretory vesicles. The uptake of 18 F-DOPA-H was significantly increased at time points 30-60 min. This finding may be due to the filling degree of the vesicles. Because there is probably some residual VMAT2 activity and because 18 F-DOPA-H is present at a concentration lower than the concentration of endogenous substrates, it does not suffer in the same extent from direct inhibition of VMAT2 transporter function as 18 F-DOPA-L and . Overview cellular uptake mechanism of 18 F-DOPA. 18 F-DOPA is taken up by LAT in exchange for other neutral amino acids (e.g., leucine). Enzyme AADC metabolizes 18 F-DOPA to 6-18 F-fluorodopamine, which in turn can be either sequestered in secretory vesicles by VMAT or degraded by other enzymes, such as MAO, to break down products that are rapidly cleared from the cell. endogenous substrates. Because the vesicles are therefore less filled with endogenous substrates due to partial inhibition of VMAT2, the negative feedback loop, resulting in downregulation of VMAT2, has not been activated (24) . This indirect effect of tetrabenazine treatment may have increased the uptake of 18 F-DOPA-H.
The predominant form of MAO in the gastrointestinal tract and associated tumors is MAO-A. The expression of MAO-A is increased and associated with dedifferentiation and metastatic potential in prostate cancer (25) , whereas MAO-A expression is downregulated in pheochromocytomas resulting in the formation of a large quantity of catecholamines (26) . The expression of MAO-A in gastroenteropancreatic neuroendocrine tumors is generally high, which allows for MAO-A imaging using PET (27) . Pharmacologic inhibition of MAO by pargyline did not result in any significant differences in the uptake of 18 F-DOPA-H and 18 F-DOPA-L. Pargyline is an inhibitor with about a 30-fold selectivity toward MAO-B over MAO-A, but at the high concentrations applied in the in vitro experiments it acts as a nonselective inhibitor of both subtypes of MAO.
To discover whether the saturation effects discussed above have implications on the distribution and imaging properties of the PET tracer in vivo, 18 F-DOPA-H and 18 F-DOPA-L were compared in an animal model for neuroendocrine tumors. In mice that were pretreated with carbidopa, there were no statistically significant differences found between 18 F-DOPA-H and 18 F-DOPA-L with respect to the tracer uptake, the time-activity curve, or the fraction converted to 6-18 F-fluorodopamine at the end of the scan. The saturation effects as observed in the in vitro experiments had no implications for the imaging properties of the novel 18 F-DOPA-H in comparison to the conventional 18 F-DOPA-L.
Several explanations for the different findings between the in vitro and the in vivo experiments are possible. The most logical explanation is that the saturation effects in the in vitro experiments were seen only under specific experimental conditions, for which either thermal or pharmacologic inhibition was applied. Although carbidopa has been administered to the mice, carbidopa mainly inhibited the peripheral metabolism.
Furthermore, the total load of administered 18 F-DOPA in the in vivo model (650 MBq/kg) is lower than the load of 18 F-DOPA in the incubation solution containing the BON-1 cells in an in vitro experiment (200 kBq in a solution of 1 mL, 200 MBq/kg). This difference in administration alone makes the observation of saturation effects in in vivo models less probable, even for 18 F-DOPA-L, which is a comforting message, because scaling up from an in vivo model in small models to clinical application of this PET tracer for the imaging of neuroendocrine tumors will further decrease the load of 18 F-DOPA (63 MBq/kg). The absence of saturation effects in vivo means that the novel 18 F-DOPA-H is biologically equivalent to conventional 18 F-DOPA-L for imaging neuroendocrine tumors in mouse models.
The main advantages of 18 F-DOPA-H are its facile and easierto-implement production method and the dramatic reduction in the administered mass of pharmacologically active 19 F-DOPA. The latter might prevent adverse reactions such as induction of a carcinoid crisis. In the event in which administration of 18 F-DOPA led to a carcinoid crisis, 5.63 mg of compound were administered to the patient (28) . Whether the properties of 18 F-DOPA-H with a 3-orders-of-magnitude higher specific activity differ from those of 18 F-DOPA-L in imaging of the dopamine biosynthesis pathway in other diseases, such as Parkinson disease, remains to be investigated. As several proteins involved in the uptake mechanism of
